Video content above is prompted by the following: How has the role of oncology pharmacists in managing mCRC evolved, particularly in enabling medication adjustments, refills, and prescribing supportive care medications? What impact has this expanded role had on patient outcomes? […]
Evolution of Oncology Pharmacy Practice in mCRC Read More »
Video content above is prompted by the following: What is the typical patient journey for an individual with mCRC, and where are pharmacists involved? How do pharmacists collaborate with oncologists and other multidisciplinary team members to provide care for patients
Mapping the Pharmacist’s Role in mCRC Management Read More »
Video content above is prompted by the following: What practical strategies does your institution use to manage treatment-related toxicities with third-line therapies for mCRC? In your experience, how have the third-line therapy options impacted your patients’ quality of life? Source
Quality of Life and Patient Outcomes in mCRC Treatment Read More »
Video content above is prompted by the following: What additional factors do you consider when determining the most effective sequence of these therapies (fruquintinib, regorafenib, trifluridine + tipiracil ± bevacizumab)? What further research is needed to understand optimal sequencing of these
Optimizing Treatment Sequencing in Advanced Colorectal Cancer Read More »
Video content above is prompted by the following: Provide an overview of the third-line treatment options for mCRC for patients with disease that has progressed through all available regimens. Fruquintinib Regorafenib Trifluridine + tipiracil ± bevacizumab Source link Scott Soefje, PharmD,
Treatment Options in mCRC: A Clinical Overview Read More »
Video content above is prompted by the following: Provide an overview of the third-line treatment options for mCRC for patients with disease that has progressed through all available regimens. Fruquintinib Regorafenib Trifluridine + tipiracil ± bevacizumab Source link Scott Soefje, PharmD,
Third-Line Treatment Options in mCRC: A Clinical Overview Read More »
Video content above is prompted by the following: When selecting third-line treatments for mCRC, how do you balance safety, efficacy, and overall patient prognosis? How do the toxicity profiles of fruquintinib, regorafenib, and trifluridine + tipiracil ± bevacizumab differ, and how
Making Informed Treatment Decisions in mCRC Read More »
